Akihiro Morinaka

OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam ‘enhancer’

Akihiro Morinaka, Yuko Tsutsumi, Mototsugu Yamada et al. · Journal of Antimicrobial Chemotherapy · 2015 · 171 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes

David M. Livermore, Shazad Mushtaq, Akihiro Morinaka et al. · Journal of Antimicrobial Chemotherapy · 2012 · 51 citations

Life Sciences, Microbiology, Pharmacology +16

Metallo-β-lactamase inhibitory activity of phthalic acid derivatives

Yukiko Hiraiwa, Akihiro Morinaka, Takayoshi Fukushima et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 49 citations

Pharmacy, Medicinal Chemistry, Pharmacology +7

X-ray crystallographic analysis of IMP-1 metallo-β-lactamase complexed with a 3-aminophthalic acid derivative, structure-based drug design, and synthesis of 3,6-disubstituted phthalic acid derivative inhibitors

Yukiko Hiraiwa, Jun Saito, Takashi Watanabe et al. · Bioorganic & Medicinal Chemistry Letters · 2014 · 42 citations

Pharmacy, Chemistry, Medicinal Chemistry +11

<i>In Vitro</i> and <i>In Vivo</i> Activities of OP0595, a New Diazabicyclooctane, against CTX-M-15-Positive Escherichia coli and KPC-Positive Klebsiella pneumoniae

Akihiro Morinaka, Yuko Tsutsumi, Keiko Yamada et al. · Antimicrobial Agents and Chemotherapy · 2016 · 26 citations · Full text

Pharmacy, Microbiology, Pharmacology +17